ContraVir to Highlight Clinical Data from Ongoing Phase 2a Study of Tenofovir Exalidex (TXL™) for Treating Hepatitis B
EDISON, N.J., Feb. 14, 2017 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present clinical data at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) to be held February 15-19, 2017, at the Shanghai International Convention Center.
John Sullivan-Bolyai, MD, MPH, Chief Medical Officer of ContraVir, will give an oral presentation highlighting Phase 2a data for Tenofovir Exalidex (TXL™), formerly CMX157, the Company's highly potent lipid prodrug of the successful antiviral drug tenofovir (Viread®) for treating hepatitis B virus (HBV). TXL™ utilizes natural lipid uptake pathways to target drug delivery to the liver, resulting in lower systemic exposure to tenofovir. TXL™ showed comparable antiviral activity to Viread® and continues to be safe and well tolerated by HBV patients in the study.
Title: Pharmacokinetics, Safety and Tolerability of CMX157, a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects
Date: Sunday, February 19, 2017
Time: 10:00 am China Standard Time
Location: Shanghai International Convention Center
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action: Tenofovir Exalidex (TXL™, formerly CMX157), a highly potent analog of the successful antiviral drug tenofovir currently in Phase 2a, which has demonstrated the potential for low, once a day dosing compared to Viread® and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing Valnivudine™ (formerly FV-100), an orally available nucleoside analogue prodrug for the treatment of herpes zoster, or shingles, in a Phase 3 clinical trial. In addition to direct antiviral activity, Valnivudine™ has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study. For more information visit www.contravir.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on ContraVir's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. ContraVir does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in ContraVir's Form 10-K for the year ended June 30, 2016, and other periodic reports filed with the Securities and Exchange Commission.
For further information, please contact:
Director of Investor Relations
email@example.com; (732) 902-4028
SOURCE ContraVir Pharmaceuticals, Inc.